

Perspectives
in
Neuro
Pharmacology

Perspectives in Neuropharmacology

A TRIBUTE TO JULIUS AXELROD

EDITED BY

SOLOMON H. SNYDER

Departments of Pharmacology and
Experimental Therapeutics and Psychiatry
The Johns Hopkins University School of Medicine

New York
OXFORD UNIVERSITY PRESS
London 1972 Toronto

Copyright © 1972 by Oxford University Press, Inc.
Library of Congress Catalogue Card Number 72-183869
Printed in the United States of America

Contributors

Jacques de Champlain
Centre de Recherches en Sciences
Neurologiques
Faculté de Médecine
Université de Montréal

Arnold Joel Eisenfeld
Departments of Pharmacology
and Internal Medicine
Yale University School of Medicine

John D. Fernstrom
Department of Nutrition and
Food Sciences
Massachusetts Institute of Technology

Jacques Glowinski
Groupe Neuroparmacologie
Biochimique
Collège de France

Georg Hertting
Institute of Pharmacology
University of Vienna

Leslie L. Iversen
Department of Pharmacology
University of Cambridge

Seymour S. Kety
Department of Psychiatry
Harvard Medical School

Irwin J. Kopin
Laboratory of Clinical Science
National Institute of Mental Health

Perry B. Molinoff
Department of Pharmacology
University of Colorado
School of Medicine

Lincoln T. Potter
Department of Biophysics
University College London
After September 1972:
Department of Pharmacology
University of Miami School of Medicine

Sune Rosell
Department of Pharmacology
Karolinska Institutet

Solomon H. Snyder
Departments of Pharmacology and
Experimental Therapeutics
and Psychiatry
The Johns Hopkins University
School of Medicine

Josef Suko
Institute of Pharmacology
University of Vienna

Kenneth M. Taylor
Department of Pharmacology
University of Otago
Dunedin, New Zealand

Hans Thoenen
Department of Pharmacology
Biocenter of the University of Basel

Richard J. Wurtman
Department of Nutrition and
Food Science
Massachusetts Institute of Technology

Acknowledgments

A special note of gratitude is due to Hoffman-LaRoche, Inc. for a very generous contribution that helped bring the authors together in a conference that led to this book. For their assistance in this same effort we would also like to thank Eli Lilly and Company, Geigy Pharmaceuticals, McNeil Laboratories, Inc., the Merck Institute for Therapeutic Research, the New England Nuclear Corporation, E. R. Squibb and Sons, Inc., Sterling Drug Incorporated, Schering Corporation and the Bayer A. G. Company. We are particularly grateful to Dr. William Manger for enabling some of this work to be presented at the Catecholamine Club meeting in Chicago in 1971.

Chapter 2 The work reported in this chapter was supported by a grant from the British Medical Research Council.

Chapter 3 This research was supported by USPHS grants NS-07275, MH-18501, GM-16492, and NIMH Research Scientist Development Award K3-MH-33128 to SHS. The authors would like to thank Birgitta Brown for her inspired and devoted technical assistance. Some of these studies were conducted in collaboration with Michael J. Kuhar, Anne B. Young, Candace D. Pert, David G. Brown, and Eduard Gfeller.

Chapter 5 Original Research reported in this chapter was supported by Grants HD-02498 and CA 10748 and Contract NIH 70-2258.

Chapter 6 Studies performed in our laboratory were supported by grants from the United States Public Health Service (AM-11709 and AM-14228), the National Aeronautics and Space Administration (NGR-22-009-272), and the John A. Hartford Foundation.

Chapter 7 The work presented here has been supported by grants from the Swedish Medical Research Council (Grant No. B71-40X-731-06), Svenska Lakaresallskapet and Karolinska Institutet.

Chapter 8 This work was partly supported by grants to the Medical Research Council group in Neurological Sciences and by grants of the Quebec Heart Foundation.

The author wishes to acknowledge the stimulating collaboration with Dr. Julius Axelrod in the studies carried out on experimental hypertension. Without his advice, enthusiasm and encouragement these studies would not have been possible. The friendly and fruitful collaboration with Dr. Lawrence R. Krakoff and Dr. Robert A. Mueller has also been essential in pursuing these studies. The skillful technical help of Miss Marie-Reine Corbeil B.Sc. and Miss Solange Imbault, in more recent studies, is gratefully acknowledged. The author also wishes to express his gratitude to Miss Danielle Beaulieu for her efficient secretarial assistance in the preparation of the manuscript.

Figures 2, 3, 4, 6, 7, 9, 12, 13, 14 have been reproduced from previously published work with kind permission of *Circulation Research*. Figures 10 and 15 have been reproduced from previously published studies in *L-DOPA and Parkinsonism*, 1970, with the kind permission of the F. A. Davis Co. (Philadelphia).

Chapter 11 This contribution was written in the author's private capacity. No official support nor endorsement by the U. S. Public Health Service is intended nor should be inferred.

Chapter 12 The author is very grateful to Mrs. M. H. Lévi and E. Monsonégo for their excellent assistance in the preparation of the manuscript.

The various investigations reported were supported in part by grants of the I.N.S.E.R.N., C.N.R.S., D.R.M.E., D.G.R.S.T., Fondation de la recherche médicale, Société des usines chimiques Rhône-Poulenc, and N.I.M.H. (U.S.A.).

Contents

1. Julius Axelrod: A Triumph for Creative Research, 3
SEYMOUR S. KETY
2. Isolation of Cholinergic Receptor Proteins, 9
L. T. POTTER AND P. B. MOLINOFF
Introduction, 9
Recognition of Isolated Receptors, 13
Isolation of the Cholinergic Receptor of Torpedo Electric Tissue, 21
References, 39
3. Histamine in the Brain: A Neurotransmitter?, 43
SOLOMON H. SNYDER AND KENNETH M. TAYLOR
Histamine Estimation in Brain Tissue, 44
Regional Localization of Histamine in Mammalian Brain, 49
The Subcellular Localization of Histamine and Histamine Methyltransferase in Rat Brain, 51
Nuclear Localization of Histamine in Neonatal Rat Brain, 57
Histamine Turnover in Rat Brain, 61
Acceleration of Brain Histamine Turnover and Partial Depletion by Stress, 66
Histamine Release by Depolarization of Brain Tissue, 69
Unanswered Questions, 70
References, 72
4. The Uptake, Storage, Release, and Metabolism of GABA in Inhibitory Nerves, 75
LESLIE L. IVERSEN
GABA as an Inhibitory Neurotransmitter Substance, 76
Biochemistry and Pharmacology of GABA Synapses, 83
References, 108

5. Interaction of Estrogens, Progestational Agents, and Androgens with Brain and Pituitary and Their Role in the Control of Ovulation, 113

ARNOLD JOEL EISENFELD

Radioactive Estrogen Interaction with the Brain, 114

Radioactive Progesterone Interaction with the Brain, 129

Radioactive Androgen Interaction with the Brain, 130

Mechanism of Action, 131

Regulation of Ovulation, 133

Role of Estrogens and Progestational Agents in the Regulation of Ovulation, 135

6. L-Tryptophan, L-Tyrosine, and the Control of Brain Monoamine Biosynthesis, 143

RICHARD J. WURTMAN AND JOHN D. FERNSTROM

Biosynthesis of Brain Monoamines, 145

Control of Brain Levels of L-Tyrosine and L-Tryptophan, 156

Experimental Evidence Relating the Availability of L-Tyrosine and

L-Tryptophan to Brain Monoamine Synthesis, 169

References, 189

7. The Sympathetic Neuro-Humoral System and White Adipose Tissue, 195

SUNE ROSELL

Cholinergic Innervation of Adipose Tissue, 195

Adrenergic Innervation of Adipose Tissue, 196

Responses to Sympathetic Nerve Activity, 197

Responses to Circulating Catecholamines, 207

Fate of the Adrenergic Transmitter Substance in Subcutaneous Adipose Tissue, 207

Adipose Tissue and Hemorrhagic Shock, 209

References, 211

8. Hypertension and the Sympathetic Nervous System, 215

JACQUES DE CHAMPLAIN

The Autonomic Nervous System and the Control of Blood Pressure, 216

Vascular Reactivity in Hypertension, 218

The Sympathetic Nervous System in Experimental Hypertension, 221

The Sympathetic Nervous System in Human Hypertension, 253

References, 260

9. Influence of Neuronal and Extraneuronal Uptake on Disposition, Metabolism, and Potency of Catecholamines, 267

GEORG HERTTING AND JOSEF SUKO

Historical Remarks, 268

Properties of the Sympathetic Neuron, 270

Experiments with the Isolated Spleen, 273

Fate of ^3H -Dopamine Taken Up into the Rat Heart, 289

The Influence of Different Perfusion Concentration on the Metabolism of ^3H -DA, 290

References, 297

10. Chemical Sympathectomy: A New Tool in the Investigation of the Physiology and Pharmacology of Peripheral and Central Adrenergic Neurons, 301

H. THOENEN

Peripheral Sympathetic Nervous System, 302

Central Nervous System, 318

Reversible and Irreversible Chemical Sympathectomy: Comparison with Surgical and Immunological Methods, 326

Compensatory Mechanisms, 329

Mechanism of Action, 330

References, 335

11. False Aminergic Transmitters, 339

IRWIN J. KOPIN

Origin of the Concept of "False" Transmitters, 339

Nonspecificity of Synthesis, Storage, and Release of Amines, 340

Selective Release of Newly Synthesized Neurotransmitters, 342

Serotonin Storage in Catecholaminergic Neurons, 344

Catecholamines in Serotonin Storage Sites, 345

References, 347

12. Some New Facts About Synthesis, Storage, and Release Processes of Monoamines in the Central Nervous System, 349

J. GLOWINSKI

Introduction, 349

Noradrenergic Neurons, 350

Dopaminergic Neurons, 365

Serotonergic Neurons, 383

References, 400

Perspectives in Neuropharmacology

A TRIBUTE TO JULIUS AXELROD

EDITED BY

SOLOMON H. SNYDER

Departments of Pharmacology and
Experimental Therapeutics and Psychiatry
The Johns Hopkins University School of Medicine

New York
OXFORD UNIVERSITY PRESS
London 1972 Toronto

1

Julius Axelrod: A Triumph for Creative Research

SEYMOUR S. KETY

Scientists, like journalists, are sometimes "scooped" by their colleagues, and it is not unusual, especially among those who work in the field of the catecholamines, to learn that one's very exciting finding has been anticipated by a group in Goteborg or Stockholm. We didn't realize, however, until quite recently, into what high circles in Sweden that tendency had penetrated.

More than a year ago, in January 1970, several former fellows of Julius Axelrod—Sol Snyder, Jacques Glowinski, Leslie Iversen, Hans Thoenen, and Linc Potter—met at a neurotransmitter conference in Paris, and decided to honor their mentor by arranging a grand reunion of all the fellows and associates with whom Axelrod had shared his genius, to be followed by the publication of a *Festschrift*. There was not the usual occasion for this since Julie was not about to reach some convenient chronological milestone and hadn't the remotest idea of retiring. It was simply a spontaneous expression of their affection and admiration for him and a recognition of his contributions to science. I was given the privilege of writing this introduction to the *Festschrift*—the only contribution which was to be personal.

It was decided to wait until the Federation meeting of 1971 and—the rest is history. On October 15, 1970, while he was sitting in a dentist's chair with his mouth full of cotton sponges, Julie learned that the Committee in Stockholm had awarded the Nobel Prize in Physiology and Medicine jointly to him, von Euler, and Katz. (It is rumored that there has been a sharp rise in the number of scientists coming for dental checkups since that time.)

Sol Snyder wrote me that day, exultant, but also concerned about how that affected the plans for the *Festschrift*. It was soon agreed, however, that the plans for this tribute were not to be altered, since the action of the Nobel Committee simply confirmed the conviction that we were on the right track!

It is clearly difficult to avoid the "halo" effect (that term has never seemed more appropriate) and to speak of Julie as we would have done last April. Yet the feelings we want to express are those which have been shared for a long time by all who were associated with him. His scientific contributions gained him international recognition but it is his human qualities which have so endeared him to his colleagues.

It is not necessary to do more than briefly summarize Axelrod's scientific contributions. A major segment of neuropharmacology and experimental psychiatry depends upon his elucidation of the biochemical and physiological processes involved in the storage, release, and inactivation of norepinephrine at the adrenergic synapse, which has made possible an understanding of the role of that amine in neurotransmission and a clarification of the mechanism of action of numerous drugs and hormones that affect adrenergic activity peripherally and centrally.

In 1957 he described the O-methylation pathway in the metabolism of catecholamines, and shortly thereafter demonstrated its importance in the inactivation of epinephrine in animals and man, characterizing the enzyme involved and its distribution in the mammalian organism. Within a few years and based largely upon his work, knowledge of the metabolism of catecholamines advanced from almost total ignorance to characterization of their major and minor pathways and metabolites. With Glowinski and Kopin he extended this knowledge to the metabolism of catecholamines in the brain.

His studies, with Whitby and Hertting, of the effects of psychotropic drugs on the uptake of ^3H -norepinephrine by sympathetically innervated tissues led to his recognition of the most important mechanism for the inactivation of norepinephrine at the adrenergic synapse and initiated a major area of current research activity on the anatomical, physiological, and pharmacological aspects of this process.

With Wurtman and Snyder he adduced evidence for the regulation of biogenic amine synthesis under environmental variations throughout the body but especially in the pineal gland, an organ resurrected by Wurtman and himself from historic neglect. Steroid hormones of the adrenal cortex

were shown to regulate epinephrine formation in the adrenal gland. More recently, with Mueller and Thoenen, he has demonstrated what appears to be an induction of tyrosine hydroxylase following increased sympathetic activity. And currently, together with Weinshilbaum, Molinoff, and Coyle, he has explored the regulation of dopamine hydroxylase and its "exocytic" release by nerve impulses.

His scientific talents are so unusual that one senses them early in one's association with him. Ten years ago they impressed me in this way: "In all of his contributions success has been much less attributable to good fortune and much more to a unique ability to develop imaginative new concepts, to select and perform crucial experiments and to stimulate the activity and productivity of others in the field." These are some of the qualities which contribute to Axelrod's creativeness, but there are many more.

Sol Snyder describes the experience of many of the research associates who have come under his influence: "Perhaps the greatest lesson Julie taught was that science is fun and exciting . . . I was struck by his intense involvement in experiments he was doing. He would lean over the scintillation counter urging it on to higher and higher counts with impatient 'body English' (a trait I inherited, and a tradition that the new computerized machines sadly have laid to rest) . . . What was quite evident then . . . was his scientific vision. He saw (and still perceives) the farthest reaching implications of apparently trivial data. And he would put forth important ideas in such deceptively simple ways that, at first glance, they seemed incredibly naive."

The excitement which Julie derived from his experiments and his ability to read what apparently mundane results were saying are certainly two of his outstanding characteristics as a scientist, and they have played a crucial role in his most important discoveries. When he saw the abstract by Armstrong and McMillan in the Federation Proceedings reporting the presence of 3-methoxy-4-hydroxymandelic acid in the urine of patients with pheochromocytoma, he immediately recognized the importance of the possible direct O-methylation of catechols and carried out his first experiment that very afternoon. Incubating epinephrine with the soluble supernatant fraction of liver, ATP, and methionine, he saw the catecholamine disappear—"right before my eyes"—to be replaced by a new compound which appeared to be the methylated derivative. He communicated his excitement to Witkop, who with Senoh synthesized the authentic O-methyl-

epinephrine in short order, providing Axelrod with a means of proving the identity of his new metabolite.

Another flash of insight led to the discovery of the reuptake mechanism as the major means by which the synaptic action of catecholamines is terminated. When he, Weil-Malherbe, and Tomchick examined the fate of tritiated epinephrine and, a little later, with Whitby, the disposition of norepinephrine, they found high concentrations of the labelled amines in certain tissues. I remember Julie excitedly telling me that the labelled catecholamines were concentrated in the tissues with the richest sympathetic innervation, convinced even then that they were taken up by the sympathetic nerve endings. Within a year Hertting and he had the evidence to permit their conclusion that reuptake of norepinephrine at sympathetic nerve endings occurred.

Perhaps the most remarkable thing about Julie is his ability to maintain an indomitable scientific conviction without losing his humility and warmth in human relationships. One of his associates wrote about him thus: "I would like to try to describe the personality of Julie from the point of view of a younger European scientist who has worked (and suffered) in the atmosphere of the 'Herr Professor and Geheimrat.' What a tremendous contrast to Julie's lab!" Hans Thoenen describes his human side in a way which needs no embellishing: "Besides his extraordinary scientific qualities Julie showed the ability to create a highly stimulating but at the same time pleasant atmosphere in his laboratory, determined by his kindness, tolerance, and great modesty. It certainly would be possible to find people with either the scientific or the human qualities of Julie, but the combination of both is unique in him."

There are some special meanings for many of us in Julie's achievements and the world-wide recognition they have so eminently deserved. He returned from Stockholm last December by way of Israel, where he received a hero's welcome. He gave strength and confidence to the Research Institutes in Bethesda and to the philosophy they have represented. He reinforced the viability of pharmacology as a challenging and intellectually satisfying discipline. But what he has done at an especially crucial time has been to exemplify the importance and the productivity of research which is undirected and untargeted, except by scientific insight.

Our society is now laboring under a well-meaning but nevertheless false assumption that the great needs we have belatedly recognized in the provision and distribution of physical and mental health care must necessarily

compete with research and the acquisition of new knowledge. Arbitrary ceilings have thus been put on research funds and the training of new investigators. Moreover, like the goose that laid the golden eggs, even this commitment to research is being tampered with and operated on in the erroneous belief that by channeling them we can somehow accelerate the processes of creativity and scientific discovery. Axelrod is an emphatic refutation of that notion.

When I became chief of the Laboratory of Clinical Science in 1956, I felt that it would be worthwhile to test the hypothesis which was then current, that abnormal metabolites of epinephrine circulation in the blood were the cause of schizophrenia. If one could use a small dose of epinephrine with very high specific radioactivity, then, with the help of chromatography and the new liquid scintillation counters which were becoming available, one might hope to characterize some of the normal and abnormal metabolites. It wasn't a bad plan as targetted research goes, and I pursued it in the modest way it deserved so as not to disturb the ecology of the laboratory. Seymour Rothschild agreed to attempt the synthesis of tritium-labelled epinephrine of the required activity. In the year it took before the first successful batch arrived, Axelrod (who was not part of the plan) had discovered the O-methylation pathway and characterized the various metabolites of epinephrine. As a minor spin-off of his work, the search for abnormal metabolites of epinephrine in schizophrenia was greatly facilitated, but—much more important—his contributions have had implications for psychiatry which were simply undreamed of in 1956.

It is quite fortunate that there were no administrative or legislative directives to put the funds of the Laboratory into mission-oriented research at the expense of the individual creativity of its scientists, no cost-benefit analyses prematurely and inappropriately applied, no requirement to answer for duplication of effort.

Axelrod has courageously voiced his concerns regarding the dangers of constricting the funds, restricting the training of new investigators, and channeling research support into illusory hierarchies of relevance. We hope his advice is heeded, for no one knows better than he the ingredients of scientific discovery.

compare with research and the acquisition of new knowledge. Arbitrary feelings have thus been put on research funds and the training of new investigators. Moreover, like the goose that laid the golden eggs, even this commitment to research is being tampered with and operated on in the erroneous belief that by channeling them we can somehow accelerate the progress of creativity and scientific discovery. Axelrod is an emphatic restatement of that notion.

When I became chief of the Laboratory of Clinical Science in 1956, I felt that it would be worthwhile to test the hypothesis which was then current, that abnormal metabolites of epinephrine circulation in the blood were the cause of schizophrenia. If one could use a small dose of epinephrine with very high specific radioactivity, then, with the help of chromatography and the new liquid scintillation counters which were becoming available, one might hope to characterize some of the normal and abnormal metabolites. It wasn't a bad plan as targeted research goes, and I pursued it in the modest way it deserved so as not to disturb the ecology of the laboratory. Seymour Rothchild agreed to attempt the synthesis of tritium-labelled epinephrine of the required activity. In the year it took before the first successful batch arrived, Axelrod (who was not part of the plan) had discovered the O-methylated pathway and characterized the various metabolites of epinephrine. As a minor spin-off of his work, the search for abnormal metabolites of epinephrine in schizophrenia was greatly facilitated, but—much more important—his contributions have had implications for psychiatry which were simply undreamed of in 1956.

It is quite fortunate that there were no administrative or legislative directives to put the funds of the Laboratory into mission-oriented research at the expense of the individual creativity of its scientists, no cost-benefit analyses prominently and inappropriately applied, no requirement to answer for duplication of effort.

Axelrod has courageously voiced his concerns regarding the dangers of constricting the funds, restricting the training of new investigators, and channeling research support into illusory hierarchies of relevance. We hope his advice is heeded, for no one knows better than he the ingredients of scientific discovery.